ABOS Latest Press Releases

-- October 30, 2026 --

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer's Disease; Trial Did Not Meet Primary Endpoint Globe Newswire 7:00 AM

-- October 26, 2026 --

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights Globe Newswire 7:00 AM

-- October 22, 2026 --

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference Globe Newswire 7:30 AM

-- October 19, 2026 --

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026 Globe Newswire 4:00 PM

-- September 10, 2026 --

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 Globe Newswire 4:00 PM

-- September 2, 2026 --

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 4:00 PM

-- August 12, 2026 --

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights Globe Newswire 7:00 AM

-- August 5, 2026 --

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 Globe Newswire 4:00 PM

-- July 15, 2026 --

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery (EBD ) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC) 2026 Globe Newswire 7:30 AM

-- July 7, 2026 --

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery (EBD ) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC) 2026 Globe Newswire 7:30 AM

-- June 17, 2026 --

JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo Technology Platform Business Wire 12:30 PM

-- June 16, 2026 --

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery (EBD ) Development Candidates for the Treatment of Alzheimer's Disease Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes